FGP
SNDX icon

Freestone Grove Partners’s Syndax Pharmaceuticals SNDX Stock Holding History

Freestone Grove Partners’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,457
Closed -$145K – 884
2025
Q2 		$145K Sell
15,457
-1,507
-9% -$16.6K ﹤0.01% 642
2025
Q1 		$208K Buy
+16,964
New +$239K ﹤0.01% 535

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Freestone Grove Partners's SNDX Position: Q3 2025 in Review

Freestone Grove Partners sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 15,457 shares — an estimated $145K sold.

Freestone Grove Partners first reported a position in SNDX in Q1 2025 and held it in 2 quarters. The position peaked at $208K in Q1 2025. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Freestone Grove Partners reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 15,457 Syndax Pharmaceuticals shares in Q3 2025, an estimated $145K.
  • Freestone Grove Partners first reported a position in Syndax Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Freestone Grove Partners's Syndax Pharmaceuticals position peaked at $208K in Q1 2025.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Freestone Grove Partners's 13F filing for Q3 2025, filed 14 Nov 2025.